Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
MWN-AI** Summary
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene editing company, recently announced that findings from a preclinical study of its PBGENE-DMD therapy will be featured in a poster presentation at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, scheduled for March 8-11 in Orlando, Florida. The presentation, titled "PBGENE-DMD gene editing treatment leads to safe and long-term functional improvement in humanized DMD-disease mouse model," emphasizes the therapy’s potential to significantly improve the safety and long-term efficacy of muscular dystrophy treatments.
PBGENE-DMD employs a unique gene excision mechanism, distinguishing it from existing therapies like microdystrophin and exon skipping treatments. It aims to provide substantial functional muscle enhancement for Duchenne muscular dystrophy (DMD) patients with mutations between exons 45 and 55, which affect approximately 60% of boys with DMD. The treatment involves a single adeno-associated virus (AAV) encoding two ARCUS proteins designed to generate a naturally-expressed, nearly full-length dystrophin protein.
Preclinical studies showcased PBGENE-DMD’s ability to effectively target and edit key muscle types, resulting in significant, durable functional improvements in a humanized DMD mouse model. The therapy restored nearly full-length dystrophin production across essential muscles, including cardiac and skeletal tissues, and also modified muscle satellite cells, which are critical for long-term muscle function.
PBGENE-DMD has already received Investigational New Drug clearance from the FDA, enabling the start of clinical trials. The therapy has previously attained Rare Pediatric Disease and Orphan Drug designations, underscoring its potential as a groundbreaking treatment for DMD. As the conference approaches, stakeholders will look to further insights into this promising therapeutic approach.
MWN-AI** Analysis
Precision BioSciences (Nasdaq: DTIL) recently announced an upcoming presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, showcasing promising preclinical data on its PBGENE-DMD gene editing therapy. This announcement could have significant implications for the company’s stock performance, particularly as it continues to position itself as a leader in gene editing technology for Duchenne Muscular Dystrophy (DMD).
Given the existing challenges associated with DMD treatments, the marketplace presents a substantial opportunity for PBGENE-DMD. The therapy's unique approach—targeting mutations between exons 45-55 using its proprietary ARCUS platform—could address the medical needs of up to 60% of boys with DMD, which is a compelling market proposition. The initial findings from animal models indicating safety and long-term efficacy can further bolster investor confidence as the clinical trial phase begins.
Given the advancements in regulation, particularly the recent FDA approval for Investigational New Drug clearance, investors might see this as a critical validation of the therapy's potential. The FDA's Rare Pediatric Disease and Orphan Drug designations add an additional layer of market appeal, enhancing the likelihood of accelerated approval pathways and potential partnerships or acquisition interest.
While the stock price may reflect speculative activity leading up to the presentation, investors should carefully monitor how the presentation resonates with the scientific community and potential partners. Ensure to consider the inherent risks outlined in the forward-looking statements, including the ongoing uncertainties in clinical outcomes and competitive landscape.
In sum, this development could signal an opportune entry point for investors looking to explore the biotech sector, particularly those focused on gene editing. Maintaining a balanced yet optimistic outlook, while keeping an eye on forthcoming data and market reactions, will be key to navigating Precision BioSciences' evolving landscape.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that new preclinical study data supporting the potential safety and long-term efficacy of PBGENE-DMD has been selected as a poster presentation at the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference taking place March 8-11 in Orlando, Florida.
Details of the presentation:
Abstract title : PBGENE-DMD gene editing treatment leads to safe and long-term functional improvement in humanized DMD-disease mouse model
Publication number: 142M
Type of presentation: Poster presentation
Authors: Adam Mischler, Whitney Lewis, Wendy Shoop, Traci Reddick, Dan Nazarenko, Nicole W. Heard, Ben Morris, Haley Grimason, Krsna Rangarajan, Cheng-Wei Wang, Kalpana Kodi, Dominique Burgess, Katie Poe, Gary Owens, Jeff Smith, Cassandra Gorsuch
Date: Monday, March 9, 2026
About PBGENE-DMD
PBGENE-DMD, a novel first-in-class gene editing therapy, utilizes a gene excision approach that is clearly differentiated from existing microdystrophin and exon skipping treatments. PBGENE-DMD is designed to potentially provide durable functional muscle improvement for DMD patients with mutations between exons 45 and 55, which impact up to 60% of boys with DMD. A single AAV encodes two ARCUS proteins designed to permanently edit a patient’s DNA within the dystrophin gene, resulting in a naturally-expressed, near full-length, functional dystrophin protein. Supported by robust preclinical evidence, PBGENE-DMD is designed to drive functional improvement in skeletal and cardiac muscle over time with the ability to target and edit muscle satellite cells.
In preclinical studies, PBGENE-DMD demonstrated the ability to target key muscle types involved in the progression of DMD and produced significant, durable functional improvements in a humanized DMD mouse model. PBGENE-DMD restored production of a near full-length functional dystrophin protein across multiple muscles, including cardiac tissue and various key skeletal muscle groups. In addition, PBGENE-DMD edited satellite muscle stem cells, believed to be critical for long-term durability and sustained functional improvement.
PBGENE-DMD has received Investigational New Drug clearance from the U.S. Food and Drug Administration (FDA) enabling initiation of clinical trial site activation. PBGENE-DMD was previously granted FDA Rare Pediatric Disease (RPD) and Orphan Drug (ODD) designation for the treatment of DMD.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, expectations about operational initiatives, strategies, further development including dose expansion, and timing of additional updates or data releases of PBGENE-DMD and the FUNCTION-DMD Trial; translation of results in preclinical studies of PBGENE-DMD to clinical studies in humans; expected timing and outcome of regulatory and institutional review board processes for PBGENE-DMD site activation; the potential long term efficacy of PBGENE-DMD as show in new preclinical study data; the design of PBGENE-DMD to potentially provide durable functional muscle improvement for DMD patients with mutations in exons 45-55 impacting up to 60% of boys with DMD; and the design of PBGENE-DMD to drive functional improvement in skeletal and cardiac muscle over time with the ability to target and edit muscle satellite cells. In some cases, you can identify forward-looking statements by terms such as “aim,” “anticipate,” “approach,” “belief”, “believe,” “contemplate,” “could,” “design,” “designed,” “estimate,” “expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,” “possible,” “potential,” “predict,” “project,” “pursue,” “should,” “strive,” “suggest,” “target,” “will,” “would,” or the negative thereof and similar words and expressions.
Forward-looking statements are based on management’s current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; our ability to advance product candidates into, and successfully design, implement and complete, clinical trials; changes in interim “top-line” and initial data that we announce or publish; our current and future relationships with and reliance on third parties including suppliers and manufacturers; and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025, and September 30, 2025 as any such factors may be updated from time to time in our other filings with the U.S. Securities and Exchange Commission (SEC), which are accessible on the SEC’s website at www.sec.gov and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com.
All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260218721069/en/
Investor and Media Contact:
Naresh Tanna
Vice President of Investor Relations
naresh.tanna@precisionbiosciences.com
FAQ**
How does Precision BioSciences Inc. DTIL plan to leverage the data presented at the MDA conference to attract investment and partnerships for PBGENE-DMD?
What are the key milestones Precision BioSciences Inc. DTIL expects to achieve in the clinical development of PBGENE-DMD following its FDA clearance?
How does the safety and efficacy of PBGENE-DMD, as demonstrated in preclinical studies, compare with existing DMD treatments being developed by competitors?
What strategies does Precision BioSciences Inc. DTIL have in place to mitigate the risks associated with the clinical trial phase of PBGENE-DMD?
**MWN-AI FAQ is based on asking OpenAI questions about Precision BioSciences Inc. (NASDAQ: DTIL).
NASDAQ: DTIL
DTIL Trading
-3.55% G/L:
$4.48 Last:
43,862 Volume:
$4.49 Open:
